Dr. Mathew Hall on the Impact of PSA Screening Recommendations

Mathew Hall, MD
Published: Wednesday, May 27, 2015



Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

In 2012 The US Preventive Services Task Force (USPSTF) finalized a recommendation that stated that PSA screening was unnecessary in all men. To determine if this recommendation is correct, Hall and his team measured PSA in National Comprehensive Cancer Network (NCCN) risk groups of men diagnosed with prostate cancer.

Their study looked at data from 2005 to 2013 on age, race, PSA, Gleason score, t-stage, and presence or absence of metastatic disease. The data analyzed came from 87,500 men from cancer centers throughout the country.

They found that prior to 2011 there was a slow but significant decline in the number of men with prostate cancer diagnosed with a PSA score greater than 10. After 2011, when the USPSTF recommendation was first introduced, this percentage increased at 3% per year.



Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

In 2012 The US Preventive Services Task Force (USPSTF) finalized a recommendation that stated that PSA screening was unnecessary in all men. To determine if this recommendation is correct, Hall and his team measured PSA in National Comprehensive Cancer Network (NCCN) risk groups of men diagnosed with prostate cancer.

Their study looked at data from 2005 to 2013 on age, race, PSA, Gleason score, t-stage, and presence or absence of metastatic disease. The data analyzed came from 87,500 men from cancer centers throughout the country.

They found that prior to 2011 there was a slow but significant decline in the number of men with prostate cancer diagnosed with a PSA score greater than 10. After 2011, when the USPSTF recommendation was first introduced, this percentage increased at 3% per year.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x